[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349632-105":59,"doc-detail-349632-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","stk11-mutations-and-deletions-define-an-aggressive-molecular-subgroup-of-cervical-adenocarcinoma","STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma","","Cervical adenocarcinoma represents 15%–20% of cervical cancers and is linked to worse survival and reduced benefit from screening and immunotherapy than squamous cell carcinoma. To identify its incompletely defined genomic drivers, whole-exome sequencing was performed on 302 invasive tumors, with structural variation assessed using SNP-array and whole-genome sequencing. Results were validated in 4600+ additional samples. STK11 alterations are enriched in HPV-positive adenocarcinoma, associate with younger diagnosis age, poorer outcomes, and inferior immune checkpoint inhibitor response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stk11-mutations-and-deletions-define-an-aggressive-molecular-subgroup-of-cervical-adenocarcinoma/349632/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stk11-mutations-and-deletions-define-an-aggressive-molecular-subgroup-of-cervical-adenocarcinoma/349632.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular changes define the aggressive subgroup of cervical adenocarcinoma in this study?","Question",{"text":112,"@type":113},"STK11 alterations—mutations and focal deletions—define a distinct subgroup. Whole-genome analysis also identifies recurrent events involving chromosome 19p and STK11, including breakage-fusion-bridge patterns.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does STK11 alteration status relate to HPV and tumor outcomes?",{"text":117,"@type":113},"STK11 alterations are significantly enriched in HPV-positive adenocarcinomas compared with SCC and are associated with younger age at diagnosis and poorer overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapies or biomarkers show links to STK11 alterations?",{"text":121,"@type":113},"STK11 alterations predict inferior outcomes following immune checkpoint inhibitor (ICI) therapy. The study also reports lower CD274 (PD-L1) expression in adenocarcinoma than in SCC and describes co-occurrence with YAP1 amplification.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349632,1790355716,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Medicine  \n| \u003Cbr> RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma\u003Cbr>Emma W. Robinson1,2 | Elisabeth A. Murphy3 | Anaseidy Albanez4 | Sonam Tulsyan1  | Hong Lou2 | Yi Xie1  |\u003Cbr>Weiyin Zhou2  | Qian Yang1 | Tawnjerae Joe1,5 | Tongwu Zhang1 | Jia Liu2 | Wen Luo2 | Dongjing Wu2 | Herbert Higson2 | Mathias Viard6,7 | Mary Carrington6,7,8  | Matthew Oberley3 | Hesler Morales4,9 | Lisa Mirabello1 | Enrique Alvirez10,11 | Roberto Orozco9  | Eduardo Gharzouzi12 | Michael Dean1 \u003Cbr>1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA | 2Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Rockville, Maryland, USA | 3Caris Life Sciences, Irving, Texas, USA | 4Instituto de Cancerología (INCAN), Guatemala City, Guatemala | 5Interdisciplinary Health Program, Northern Arizona University, Flagstaff, Arizona,\u003Cbr>USA | 6Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA | 7Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA | 8Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA | 9Hospital General San Juan de Dios, Guatemala City, Guatemala | 10Hospital Central Universitario“Dr. Antonio M Pineda”, Barquisimeto, Lara State, Venezuela | 11Universidad Andino de Cusco, Cusco, Peru | 12Integra Cancer Center, Guatemala City, Guatemala\u003Cbr>Correspondence: Michael Dean ([deanm@mail.nih.gov](deanm@mail.nih.gov))\u003Cbr>Received: 4 June 2026 | Revised: 31 July 2026 | Accepted: 20 August 2026\u003Cbr>Keywords: adenocarcinoma | cervical cancer | human papillomavirus | STK11 tumor suppressor | whole exome sequencing |\n| --- |\n| ABSTRACT\u003Cbr>Cervical adenocarcinoma accounts for 15%–20% of cervical cancers and is associated with poorer survival and reduced response to screening and immunotherapy compared with squamous cell carcinoma (SCC) . The genomic drivers underlying this molecular subgroup remain incompletely characterized. Whole-exome sequencing was performed on 302 invasive cervical cancers from Guatemala and Venezuela. Structural variation analysis was conducted using SNP-array and whole-genome sequencing data. Findings were replicated in more than 4600 additional cervical cancer samples from TCGA, AACR Project GENIE, MSKCC, and Caris datasets. TP53 mutations were more frequent in adenocarcinoma than SCC, particularly in HPV-negative tumors. STK11 alterations, including mutations and focal deletions, were significantly enriched in HPV-positive adenocarcinomas compared with SCC and affected 23% of adenocarcinomas overall. Whole-genome analyses identified recurrent focal deletions, inversions, chromosomal rearrangements, and breakage-fusion-bridge events involving chromosome 19p and STK11 that were not detected by exome sequencing alone. STK11 alterations were associated with younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor (ICI) therapy. STK11 alterations significantly co-occurred with YAP1 amplification but were largely mutually exclusive with PIK3CA mutation. Cervical adenocarcinomas also demonstrated significantly lower CD274 (PD-L1) expression than SCC. STK11 alterations define a distinct molecular subgroup of cervical adenocarcinoma characterized by structural disruption of chromosome 19p, younger age at onset, and poorer clinical outcomes. These findings have implications for molecular classification and future targeted therapeutic approaches in cervical cancer. |\n|  |\n| Abbreviations: AD, adenocarcinoma; ASCAT, Allele-Specific Copy Number Analysis of Tumors; BFB, breakage-fusion-bridge; HPV, human papillomavirus; ICI, immune checkpoint inhibitor; INCAN, Instituto Nacional de Cancerologia; (MoChA), MOsaic CHromosomal Alterations; SC","cbCaifSWFE6NhWQD","https://ap.wps.com/l/cbCaifSWFE6NhWQD","pdf",4120099,15,"English","# Abstract\n# Introduction\n## Background and epidemiology\n## Histological types and classification\n## Study rationale and objectives","[{\"question\":\"What molecular changes define the aggressive subgroup of cervical adenocarcinoma in this study?\",\"answer\":\"STK11 alterations—mutations and focal deletions—define a distinct subgroup. Whole-genome analysis also identifies recurrent events involving chromosome 19p and STK11, including breakage-fusion-bridge patterns.\"},{\"question\":\"How does STK11 alteration status relate to HPV and tumor outcomes?\",\"answer\":\"STK11 alterations are significantly enriched in HPV-positive adenocarcinomas compared with SCC and are associated with younger age at diagnosis and poorer overall survival.\"},{\"question\":\"What therapies or biomarkers show links to STK11 alterations?\",\"answer\":\"STK11 alterations predict inferior outcomes following immune checkpoint inhibitor (ICI) therapy. The study also reports lower CD274 (PD-L1) expression in adenocarcinoma than in SCC and describes co-occurrence with YAP1 amplification.\"}]","STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma | PDF",1790084601,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a772ad7cce10e8f821193de697a4050.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0e788e56aaeb425b837c4f8f1d46d14.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12d51cc549811af414d50a15eac19aa1.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24a97275caba86722834ef1a7254461f.webp",980,1287]